BiotechTube

OCS-01

Phase 2Active
0 watching 0 views this week⚡ Active
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Uveitis Related Cystoid Macular Edema

Conditions

Uveitis Related Cystoid Macular Edema, Cystoid Macular Edema, Postoperative

Trial Timeline

May 26, 2023 → Sep 1, 2026

NCT ID
NCT05608837

About OCS-01

OCS-01 is a phase 2 stage product being developed by Oculis Holding AG for Uveitis Related Cystoid Macular Edema. The current trial status is active. This product is registered under clinical trial identifier NCT05608837. Target conditions include Uveitis Related Cystoid Macular Edema, Cystoid Macular Edema, Postoperative.

Hype Score Breakdown

Clinical
17
Activity
12
Company
5
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT05608837Phase 2Active

Competing Products

20 competing products in Uveitis Related Cystoid Macular Edema

See all competitors
ProductCompanyStageHype Score
triamcinolone acetonide (Triesence®)Clearside BiomedicalPhase 1/2
33
4 mg CLS-TA Suprachoriodal InjectionClearside BiomedicalPhase 3
69
Baricitinib + AdalimumabEli LillyPhase 3
77
Ixekizumab Prefilled SyringeEli LillyApproved
85
adalimumabAbbViePhase 3
77
Adalimumab + Prednisone + PlaceboAbbViePhase 3
77
Adalimumab + Prednisone + PlaceboAbbViePhase 3
77
AdalimumabAbbVieApproved
85
FTY720 + Oral CorticosteroidNovartisPhase 2
52
AIN457NovartisPhase 3
77
MyforticNovartisPre-clinical
23
AIN457 + AIN457 + Placebo AIN457NovartisPhase 3
77
LFG316 + Conventional TherapyNovartisPhase 2
52
RanibizumabNovartisPhase 2
52
AIN457 + PlaceboNovartisPhase 3
77
AIN457 + AIN457 + AIN457 + PlaceboNovartisPhase 3
77
AEB071NovartisPhase 2
52
AIN457 + AIN457 + AIN457 + PlaceboNovartisPhase 3
77
Myfortic + DecortinNovartisPhase 3
77
AIN457 + AIN 457 + AIN457NovartisPhase 2
52

Other Products from Oculis Holding AG

OCS-01 + VehiclePhase 3
72
Dexamethasone Ophthalmic SuspensionPhase 3
72
Dexamethasone ophthalmic suspension (OCS-01) + VehiclePhase 3
72
Dexamethasone ophthalmic suspension (OCS-01) + VehiclePhase 2/3
60
OCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic Suspension 1.5% mg/mL + PlaceboPhase 2
47